Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients by Grenda Leite Pereira, Andréa Monteiro Tarragô, Walter Luiz Lima Neves, Pedro Vieira da Silva Neto, Priscila Sarmento de Souza, Juliana dos Santos Affonso, Keyla Santos de Sousa, Jéssica Albuquerque da Silva, Allyson Guimarães Costa, Flamir da Silva Victoria, Marilu Barbieri Victoria, Adriana Malheiro

“…This therapy has been shown to be very effective in relation to patient adherence to treatment and has shown high rates of sustained virological response (SVR). However, the immunological dynamics of patients infected with HCV is poorly understood. …”
Get full text

Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study by V. T. Ivashkin, Ye. N. Bessonova, P. O. Bogomolov, N. I. Geyvandova, K. V. Zhdanov, M. V. Mayevskaya, V. G. Morozov, V. D. Pasechnikov, I. Yu. Khomenko, A. V. Yagoda

“…Preliminary estimation of drug efficacy was based on rates of rapid and early virologic response (RVR and EVR) achievement, dynamics of biochemical tests, dynamics of blood level of peginterferon alpha and neopterin. …”
Get full text

The role of the interleukin family in liver fibrosis by Zixin Zhang, Zixin Zhang, Jiahui Wang, Hui Li, Qun Niu, Qun Niu, Yujing Tao, Yujing Tao, Xin Zhao, Xin Zhao, Zijian Zeng, Zijian Zeng, Haijian Dong, Haijian Dong

“…Relevant studies have demonstrated that effective inhibition of hepatitis B virus (HBV) replication by nucleoside (acid) analogs or polyethylene glycol alpha-interferon can lead to recovery in some patients with hepatitis B liver fibrosis, However, some patients with liver fibrosis do not show improvement, even after achieving a complete serologic and virologic response. A similar situation occurs in patients with hepatitis C-related liver fibrosis. …”
Get full text

Evolution and importance of Molecular Microbiology in the Laboratory of the Provincial Center for Hygiene, Epidemiology and Microbiology by María de Lourdes Sánchez Alvarez, Rafael Abreu Duarte, Edenis García Alvarez, Adrian Fernández García, Ermis Alexander González Martínez, Maidelys Mendoza Acosta

“…Conclusions: the progressive increase in the resolution capacity of the Molecular Biology Laboratory, together with the implementation of new diagnostic platforms, has allowed us to strengthen the detection of pathogens of clinical interest and improve virological sentinel surveillance.…”
Get full text

Combination Antiretroviral Therapy for HIV in Rwandan Adults: Clinical Outcomes and Impact on Reproductive Health up to 24 Months by Brenda Asiimwe-Kateera, Nienke Veldhuijzen, Jean Paul Balinda, John Rusine, Sally Eagle, Joseph Vyankandondera, Julie Mugabekazi, Pascale Ondoa, Kimberly Boer, Anita Asiimwe, Joep Lange, Peter Reiss, Janneke van de Wijgert

“…In the cART groups, 21% of patients required a drug change due to side effects and 11% of patients had virological failure (defined as >1,000 HIV RNA copies/mL) after 12 months of cART. …”
Get full text

Treatment failure and drug resistance among the newly reported HIV-infected patients in Taizhou City from 2020 to 2022 by LI Yan, WU Xuanhe, SHI Lu, LI Guixia, WANG Shanling, WANG Yating, CHEN Tailin, WANG Tingting, XIE Yali, SHEN Weiwei, LIN Haijiang, CHEN Xiaoxiao, HE Na

“…Among the 36 HIV-infected patients with virological failure, 27 sequences were successfully amplified, with a successful amplification rate of 75.0% (27/36). …”
Get full text

Role of alpha-fetoprotein in complex diagnostics of progressing course of chronic hepatitis B and C by I. A. Belavina, O. P. Dudanova

“…The diagnosis was verified by clinical, laboratory and morphological – with assessment of histological activity index (HAI) and histological sclerosis index (HSI), instrumental (transabdominal ultrasound, Doppler ultrasonography of portal blood flow), virologic studies. AFP level was determined by chemiluminescent solid-phase analysis by «Immulite AFP» test-systems (USA). …”
Get full text

Severe Symptomatic Primary CMV Infection in Inflammatory Bowel Disease Patients with Low Population Seroprevalence by Catherine Rowan, Ciaran Judge, Mary D. Cannon, Garret Cullen, Hugh E. Mulcahy, Elizabeth Ryan, Cillian F. De Gascun, Glen A. Doherty

“…Patients with primary CMV infection 2010–13 were identified; clinical, serologic, and virologic parameters were studied in detail. The seroprevalence of CMV in the patient population was also evaluated. …”
Get full text

Serum Lipid and Glycemic Profile in HARRT-Naïve and HARRT-Exposed HIV Patients in Enugu State, Nigeria: A Case–Control Study by Esther A. Ekwe, Birinus A. Ezeala-Adikaibe, Basden Onwubere, Julius Okoye, Collins Ugwu, Chidinma B. Nwatu, Ijoma Chinweuba, Chidimma Orah-Okpala, Raphael Anakwue, Oladipupo O. Fasa, Celestine C. Okwara, Uchechi Q. Arinze, Paschal Njoku

“…Background: Although highly active antiretroviral therapy (HAART) has improved immunologic and virologic outcomes, as well as the quality of life of human immunodeficiency virus (HIV)-positive patients, it has worsened a wide range of metabolic derangements associated with HIV/AIDS. …”
Get full text

Techniques of blood sampling for detection of African swine fever virus in wild boar and domestic pigs in the field conditions by A. S. Pershin, A. R. Shotin, E. O. Morozova, A. S. Igolkin, O. A. Manuylova, I. V. Shevchenko, А. А. Shevtsov, N. N. Vlasova

“…To collect field samples of biological material from animals for molecular genetic, virological, and serological tests, filter paper, as well as swabs, can be used. …”
Get full text

Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis by Yinan Yao, Ming Yue, Jie Wang, Hongbo Chen, Mei Liu, Feng Zang, Jun Li, Yun Zhang, Peng Huang, Rongbin Yu

“…All patients received grazoprevir plus elbasvir with or without RBV for 12 or 18 weeks. The sustained virological response (SVR) 12 weeks after end of treatment was calculated for overall and subgroups. …”
Get full text

Why and How to Treat Chronic Hepatitis C by Stephanos J Hadziyannis

“…IFN-α therapy may also prove to be effective in reducing the rate of HCC development in CHC regardless of whether a virological response is achieved, but this remains to be established.…”
Get full text

Resistance-Associated Substitutions (RAS) and Clinical Factors as Determinants of Sofosbuvir-Daclatasvir Treatment Outcomes in Chronic Hepatitis C Patients by Juferdy Kurniawan, Anugrah Dwi Handayu, Gita Aprilicia, Darlene Raudhatul Bahri, Irsan Hasan

“…All patients were followed up until 12 weeks after completion of treatment to determine the sustained virological response 12 (SVR12). Results: Out of the 58 patients, 9 patients (15.51%) did not achieve SVR.  …”
Get full text

Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study by Wencong Li, Jing Liang, Jihong An, Lingdi Liu, Yihui Hou, Lu Li, Wen Zhao, Luyao Cui, Ningning Xue, Zaid Al-Dhamin, Tao Han, Yuemin Nan, Liaoyun Zhang

“…The geographic distribution of HCV genotypes was analyzed in 2162 patients recruited from April 2018 to February 2021. Sustained virologic response rates at 12 (SVR12) or 24 (SVR24) weeks posttreatment and safety were analyzed in 405 patients who completed DAA treatment according to patient baseline characteristics and treatment. …”
Get full text

Timing of congenital cytomegalovirus diagnosis and missed opportunities by Mallory R. Baker, Xing Wang, Ann J. Melvin

“…Anticipating that infants with cCMV who are not tested at birth risk a delayed diagnosis, this study was conducted to investigate the timing of diagnosis for infants with cCMV and to determine the reasons for and impact of late diagnoses.MethodsClinical, imaging and laboratory data, hearing and developmental outcomes were abstracted from medical records between 2009 and 2021 for infants with virologically confirmed cCMV.ResultsOne hundred and twelve children with confirmed cCMV were identified. …”
Get full text

GagCM9-specific CD8+ T cells expressing limited public TCR clonotypes do not suppress SIV replication in vivo. by Lara Vojnov, Mauricio A Martins, Jorge R Almeida, Zachary Ende, Eva G Rakasz, Matthew R Reynolds, Enrique J Leon, Kim L Weisgrau, Benjamin J Burwitz, Joy M Folkvord, Marlon G Veloso de Santana, Patrícia C Costa Neves, Elizabeth Connick, Pamela J Skinner, Emma Gostick, David H O'Connor, Nancy A Wilson, Myrna C Bonaldo, Ricardo Galler, David A Price, Danny C Douek, David I Watkins

“…We carried out a series of immunological and virological assays to understand why these Gag-specific CD8(+) T cells could not control virus replication in vivo. …”
Get full text

Analytical Performances of Human Immunodeficiency Virus Type 1 RNA-Based Amplix® Real-Time PCR Platform for HIV-1 RNA Quantification by Christian Diamant Mossoro-Kpinde, Ralph-Sydney Mboumba Bouassa, Mohammad-Ali Jenabian, Serge Tonen Wolyec, Leman Robin, Mathieu Matta, Jean de Dieu Longo, Gérard Grésenguet, Laurent Andreoletti, Laurent Bélec

“…The Amplix assay showed 100% sensitivity and 99.6% specificity to diagnose virological failure in clinical samples from antiretroviral drug-experienced patients. …”
Get full text

Modern modes of chronic hepatitis B treatment in daily clinical practice by M. V. Mayevskaya, M. A. Morozova, S. A. Ondos, V. T. Ivashkin

“…At application of pegilated interferon (PEG-IFN) resistance does not develop, however frequency of adverse events is high. The low level of virologic response at of PEG-IFN treatment should be mentioned as well. …”
Get full text

Long-Term Results of the Etiotropic Therapy of Subcompensed Liver Cirrhosis in the Outcome of Chronic Hepatitis C by P. O. Bogomolov, A. O. Bueverov, V. E. Bakirova, E. O. Lyusina, E. A. Fedosyina, S. V. Koblov, O. V. Sumtsova

“…AVT in patients with LC of HCV etiology is associated with a high frequency of virologic response. Longterm follow-up results indicate a significant improvement of liver function, but also a continuing high risk of developing complications of underlying disease, primarily HCC.…”
Get full text

UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS by José Luis Piñana, Estela Giménez, Lourdes Vázquez, María Ángeles Marcos, Manuel Guerreiro, Rafael Duarte, Ariadna Pérez, Carlos de Miguel, Ildefonso Espigado, Marta González-Vicent, María Suarez-Lledó, Irene García-Cadenas, Rodrigo Martino, Angel Cedillo, Monserrat Rovira, Rafael de la Cámara, David Navarro, Carlos Solano

“…Results: Recommendations were provided for virological monitoring, including the timing and frequency of CMV DNAemia surveillance, especially during letermovir (LMV) prophylaxis. …”
Get full text